September19,2007— 美國食品藥物管理局（FDA）以及健康照護研究與品質(zhì)署（AHRQ）宣布他們將共同進行最具意義的研究
項研究將會針對大約50萬名曾使用藥物治療ADHD之兒童與成人臨床資料
一項來自FDA的聲明指出，因為ADHD的治療藥物會增加心率與血壓
聲明中表示
這項研究將會由泛德堡大學(xué)研究者團隊、以及主要研究者William D.Cooper醫(yī)師主導(dǎo)
這項研究的分析將針對所有目前在市面上使用的ADHD藥物
FDA的監(jiān)視與流行病學(xué)辦公室主任Gerald Dal Pan醫(yī)師表示，已經(jīng)有許多案例報告指出
AHRQ主任Carolyn M.Clancy在這項聲明中表示
【ADHD藥物使用的增加】
根據(jù)國家精神健康機構(gòu)，ADHD影響了大約3-5%的學(xué)齡兒童
這項聲明附帶
2007年2月
，F(xiàn)DA要求所有被核準用于治療ADHD藥物的制造廠商必須制作病患用藥須知，來提醒病患可能會有與治療有關(guān)的心血管及精神事件他們也注意到藥物相關(guān)精神不良反應(yīng)
，例如幻聽、疑神疑鬼、或是變得瘋狂，這樣的風險有上升的情形（大約1000分之一），即使是過去沒有精神疾病病史的患者。New Study to Examine Potential Cardiovascular Risks of ADHD Drugs By Susan Jeffrey
Medscape Medical NewsSeptember19,2007— The Food and Drug Administration(FDA)and the Agency for Healthcare Research and Quality(AHRQ)announced they will collaborate on "the most comprehensive study to date" of potential cardiovascular risks associated with the prescription medications used to treat attention deficit/hyperactivity disorder(ADHD).The study will examine clinical data on about500,000children and adults who have taken medications used in ADHD,looking specifically for cardiovascular risks,including myocardial infarction(MI)and stroke."Because medications used to treat ADHD can increase heart rate and blood pressure,there are concerns about the drugs' potential to increase cardiac risks," a statement from the FDA notes."It is also thought that these risks may be different for adults and children,but more evidence is needed about the long-term effects of using ADHD medications."The planned analysis follows an FDA-sponsored preliminary study that compiled information from large healthcare databases on prescription drug use,inpatient care,outpatient treatment,and health outcomes including death,the statement says.From this work,researchers identified people who took ADHD drugs over a7-year period ending in2005.The study will be coordinated by Vanderbilt University researchers,with principal investigator William D.Cooper,MD,on contract through AHRQ's Effective Health Care Program,and data analysis will be performed at Vanderbilt,Kaiser Permanente of California,the HMO Research Network,and i3Drug Safety,as well as the FDA and AHRQ.The analysis will focus on all drugs currently marketed for ADHD and look at risks associated with the drugs as a whole and grouped by class.The results are expected in about2years."Case reports have described adverse cardiovascular events in adult and pediatric patients with certain underlying risk factors who receive drug treatment for ADHD,but it is unknown whether or not these events are causally related to treatment," said Gerald Dal Pan,MD,director of the FDA's Office of Surveillance and Epidemiology."The goal of the study is to develop better information on this question.""This study highlights1of AHRQ's most important missions:to collect and analyze scientific evidence that will help patients,policymakers,and clinicians make the best possible decisions," said AHRQ director Carolyn M.Clancy in the statement.Increasing Use of ADHD DrugsAccording to the National Institute of Mental Health,ADHD affects approximately3%to5%of school-aged children and about4%of adults.Use of ADHD drugs has increased in recent years among both children and adults,the statement added."A recent AHRQ analysis of medication expenditures found3ADHD drugs — Concerta(methylphenidate hydrochloride[ALZA/McNeil Pediatrics]),Strattera(atomoxetine HCL[Eli Lilly]),and Adderall(mixed salts of a single-entity amphetamine product[Shire US])— ranked among the top5drug prescribed for children ages17years and younger," the statement notes,with an estimated $1.3billion spent in2004.Adult use is also thought to be increasing.In February2007,the FDA directed manufacturers of all drug products approved for ADHD to develop patient medication guides to alert patients to possible adverse cardiovascular and psychiatric events related to treatment.The move came after an FDA review of case reports of serious cardiovascular events including sudden death in subjects with underlying heart problems or defects and reports of stroke and MI in adults with certain risk factors.They also noted a slight increased risk(about1per1000)of drug-related psychiatric adverse events such as hearing voices,becoming suspicious for no reason,or becoming manic,even in patients without a previous psychiatric history.
本文地址:http://m.mcys1996.com/zhongyizatan/31782.html.
聲明： 我們致力于保護作者版權(quán)，注重分享，被刊用文章因無法核實真實出處，未能及時與作者取得聯(lián)系，或有版權(quán)異議的，請聯(lián)系管理員，我們會立即處理
上一篇:
選靈芝孢子粉有訣竅
Copyright ? 2023-2024 大道家園 版權(quán)所有
，此法不僅強補腎精
！做好7件事把氣血補回來" onerror="nofind(this)">
身體不適時請至正規(guī)醫(yī)院就診！勿延誤
后緣何會便秘.png)
果可能影響乳腺癌患者對手術(shù)方案的選擇.png)
性骨髓瘤易出現(xiàn)神經(jīng)病變.png)